OBT 357

Drug Profile

OBT 357

Alternative Names: MEN 1112; OBT357; OX 357; OX-001

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Menarini; Oxford BioTherapeutics
  • Class Antibodies; Antineoplastics; Fab fragments; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action ADP-ribosyl cyclase 2 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 15 Mar 2016 Phase-II development for Acute myeloid leukaemia is ongoing in Belgium, France, Germany and Italy
  • 25 Nov 2014 Phase-I clinical trials in Acute myeloid leukaemia (Relapsed or refractory disease) in Italy, France, Germany and Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top